Cargando…
Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials
INTRODUCTION: Heart failure (HF) is still a major cause of morbidity and mortality all over the world. Aim of the study was to assess the benefits and harms of sacubitril/valsartan (S/V) compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in patients wi...
Autores principales: | Hernandez, Adrian V., Pasupuleti, Vinay, Scarpelli, Nancy, Malespini, Jack, Banach, Maciej, Bielecka-Dabrowa, Agata M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259398/ https://www.ncbi.nlm.nih.gov/pubmed/37313196 http://dx.doi.org/10.5114/aoms/159113 |
Ejemplares similares
-
Diagnostic value of aldosterone to renin ratio calculated by plasma renin activity or plasma renin concentration in primary aldosteronism: a meta-analysis
por: Liu, Zhenjie, et al.
Publicado: (2022) -
Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
por: Ssentongo, Anna E, et al.
Publicado: (2020) -
Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis
por: Nuechterlein, Kaitlin, et al.
Publicado: (2021) -
Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis
por: Kaur, Upinder, et al.
Publicado: (2021) -
The effect of renin–angiotensin–aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies
por: Zhang, Kai, et al.
Publicado: (2022)